Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...

The gene therapies for cardiomyopathies market is poised for strong growth as advancements in genomic medicine accelerate the development of ...

Seasoned Biotech Entrepreneur Dr. Christian Thirion Appointed CEO of DiNATEQ AG and Group Chief Strategy & Business Development Officer; Dr. Josef El Andari Named Chief Scientific Officer of DiNAQOR ...

NeuExcell Therapeutics announced encouraging clinical results of NXL-004, the world’s first in situ conversion gene therapy ...

The treatment uses a modified, harmless virus to deliver healthy genes to a patient’s cells to treat genetic diseases. Read more at straitstimes.com. Read more at straitstimes.com.

X-linked retinoschisis gene replacement therapy, aiming to improve retinal architecture and visual function in young male ...

The top 10 PharmTech videos of the year cover advanced therapies, high-concentration biologics, major mergers and ...

This year saw notable progress in head and neck cancers, Huntington's disease, personalized genetic therapy, and heart ...

Based on initial positive results from HOPE-B, etranacogene dezaparvovec became the first gene therapy approved for adults with hemophilia B who currently use factor IX prophylaxis therapy for blood ...

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...

Hemophilia B, a genetic bleeding disorder caused by deficient factor IX activity, has traditionally required lifelong prophylactic intravenous infusions. Etranacogene dezaparvovec, a gene therapy ...

Studienergebnisse DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies 23.12.2025 / 14:36 CET/CEST ...